A paired analysis of colorectal cancer patients for whom we had data on the last FDA-approved therapy and phase I therapy (PIK3CA mutations, n=10; wt PIK3CA, n=25), there was no response noted (Table 4). Here, PIK3CA is linked to colorectal cancer.